Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) Gross Profit (2016 - 2025)

Historic Gross Profit for Immucell (ICCC) over the last 16 years, with Q3 2025 value amounting to $2.4 million.

  • Immucell's Gross Profit rose 4922.75% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year increase of 12246.53%. This contributed to the annual value of $7.9 million for FY2024, which is 10523.29% up from last year.
  • As of Q3 2025, Immucell's Gross Profit stood at $2.4 million, which was up 4922.75% from $2.8 million recorded in Q2 2025.
  • In the past 5 years, Immucell's Gross Profit registered a high of $3.4 million during Q1 2025, and its lowest value of $300775.0 during Q1 2023.
  • Over the past 5 years, Immucell's median Gross Profit value was $2.0 million (recorded in 2021), while the average stood at $2.0 million.
  • As far as peak fluctuations go, Immucell's Gross Profit tumbled by 9030.77% in 2023, and later soared by 66314.82% in 2024.
  • Over the past 5 years, Immucell's Gross Profit (Quarter) stood at $2.6 million in 2021, then tumbled by 61.25% to $992176.0 in 2022, then grew by 27.69% to $1.3 million in 2023, then skyrocketed by 123.51% to $2.8 million in 2024, then fell by 16.55% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q3 2025, $2.8 million for Q2 2025, and $3.4 million during Q1 2025.